Alcon (ALC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$10.9B

Revenue (quarter)

$2.8B

Revenue growth (year over year)

+8.74%

Gross profit (trailing twelve months)

$6.2B

Gross margin

56.85%

Net income (trailing twelve months)

$643.0M

Net income (quarter)

—

Net income growth (year over year)

−100.00%

Net margin

5.92%

Return on equity

2.94%

EPS (trailing twelve months)

$1.32

Book value per share

$44.67

P/E (trailing twelve months)

48.02

Price to book

1.43

Debt to assets

30.56%

Payout ratio

15.87%

Dividend yield

0.55%

Company profile

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

• Is Alcon (ALC) profitable?

  Yes. Alcon earned $643.0M in net income over the trailing twelve months, a net margin of 5.92%.

• How much revenue does Alcon (ALC) make?

  Alcon generated $10.9B in revenue over the trailing twelve months, up 8.74% year over year.

• What is ALC's P/E ratio?

  Alcon trades at 48.0 times trailing twelve-month earnings, on an EPS of $1.32.

• How do I buy stock in Alcon (ALC)?

  ALC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.